LSLS Immunotherapy in Cancer 12 Feb 2015 Programme

Life Science Leadership Series: Immunotherapy in Cancer 12 February 2015 Babraham Research Campus, Cambridge

Programme 08.30

09.15

Registration Welcome Tony Jones, Business Development Director, One Nucleus

09.25 Introduction to Today’s Programme

Alain Rachon, Business Developer Biotech Start-up, Merck Millipore 09.35

Chair’s Scene Setting Viia Valge-Archer, Principal Scientist, Oncology, MedImmune

09.45 An Insider View to the Recent Merck-Pfizer Immuno-Oncology Alliance

Tamara Wells, Director Business Development Oncology, Merck Serono 10.15 History and Drivers of the Current Focus on Immunotherapy

Adrian Dawkes, PharmaVentures 10.45 – 11.15

Tea/Coffee Break and networking

11.15 – 12.45

Plenary Session: Innovative Approaches to New Therapeutics

11.15 Introduction from the Chair Dr Neill Mackenzie, CBO, Biotecnol Ltd 11.20 Targeting CD95-CD95L System in Tumours

Davidson Ateh, CEO, BioMoti 11.40

Kymab: A Leader in Therapeutic Antibody Discovery and Transformational Drugs in Immuno-oncology Steve Arkinstall, Chief Scientific Officer, Kymab

12.00 ImmTACs, a New Class of Immune-oncology Therapeutic

Stephen Megit, Director of Business Development, Immunocore

12.20 A New Class of Antibody Derived T-cell Engagers

Dr Neill Mackenzie, CBO, Biotecnol Ltd 12.40 – 14.00

Lunch and Networking

14.00 – 15.05

Plenary Session: Engaging External Expertise

14.00 Introduction from the Chair 14.05 Setting a Reliable Contract with a CDO partner: Key Criteria to Consider

Florence L’Hospice, Innate Pharma 14.25 Working with PDX Models for Early Proof of Concept

Rajendra Kumari, CSO, PRECOS, a Crowne Bioscience company 14.45 A Check List for First in Man Approval

Richard Turner, Principal Consultant, Clinical Network Services (UK) 15.05 Chair’s closing remarks 15.05 – 15.45

Tea/Coffee Break and Networking

15.45 – 17.10 Plenary Session: Leveraging Partnerships and Investors to Enhance Development 15.45 Introduction from the Chair

Tony Jones, Business Development Director, One Nucleus 15.50 Managing a Successful Biodevelopment Project Through External Collaboration

Simon Boa, Head of Business Development, Merck Millipore 16.10 Patient Capital: The Cancer Research UK Pioneer Fund

Keith Blundy, CEO, Cancer Research Technology

Ian Miscampbell, Managing Partner, Sixth Element Capital LLP 16.30 Perspectives on Early Stage Investments: The Advantages of Having a Corporate VC’s Input

Hakan Goker, Investment Director, MS Ventures 16.50

Chair’s closing remarks

17.00 Thanks from One Nucleus

Tony Jones, Business Development Director, One Nucleus 17.10 Drinks Reception 18.30

Event closes

Event sponsor

Event supporters

Speaker Profiles Dr Davidson Ateh, CEO, BioMoti Davidson Ateh is a healthcare entrepreneur. He has an interdisciplinary scientific background in the physical and life sciences having completed a first degree in Biomedical Materials and a PhD in Bioengineering. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School (University of Strathclyde). Davidson has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti’s lead candidate for the unmet ovarian cancer indication has the potential to be a ground breaking cancer therapy for patients in need.

Steve Arkinstall, Chief Scientific Officer, Kymab Dr Arkinstall brings over 25 years of experience in biopharmaceutical drug discovery research across a range of disease areas and technology platforms. Previously Dr Arkinstall worked at the prestigious Glaxo Institute for Molecular Biology in Switzerland where he studied receptor-linked signal transduction pathways as a basis for new drug target identification for several therapeutic indications. Dr Arkinstall also worked for Serono in Boston USA, where he led the Serono Reproductive Biology Institute and also served as President of the Serono Research Institute with a focus on Oncology drug discovery. Following its acquisition by Merck KGaA he also played several leadership roles within Merck Serono including Head of Global Novel Biological Entities and External Innovation. Dr Arkinstall obtained his PhD (D.Phil) from the University of Oxford, UK.

Keith Blundy, Chief Executive Officer, Cancer Research Technology Keith joined CRT in 1998, became COO in 2004 and was appointed CEO in 2007. Since then he has overseen the launch of a £50m Cancer Research Technology Pioneer Fund in partnership with the European Investment Fund (EIF) to bridge the UK funding gap between cancer drug discovery and early treatment development. He has initiated risk sharing discovery alliances with AstraZeneca and Teva (formerly Cephalon), the establishment of CRT Inc in Boston (USA) as a business development arm of CRT and the further globalisation of CRT’s cancer IP development and commercialisation through becoming a partner of Cancer Therapeutics Pty in Melbourne, Australia. After completing a PhD at the John Innes Institute and a post doctoral Fulbright scholarship in the US on the regulation of plant gene expression, he spent 10 years managing and commercialising agricultural biotechnology programs before transitioning to healthcare through business development. Keith has a BSc and PhD in genetics and an MBA from the London Business School. He was formerly a director of KuDOS Pharmaceuticals Ltd and Mission Therapeutics and currently is on the board of Cytosystems Ltd and Cancer Therapeutics Pty. He is a member of Cancer Research UK’s Scientific Executive Board.

Simon Boa, Head of Business Development, Merck Millipore As Director of Commercial Development for Provantage services, Simon leads the sales and marketing team, who integrate a broad range of products and services from clone generation and GMP manufacture, to facility set up and product launch strategy. He has over 11 years’ experience in small and large molecule development, where he has worked with and advised hundreds of companies on a broad array of molecule types and indications.

Simon has completed post-doctoral fellowships in Barcelona, Budapest and Cape Town. He has an MBA from Warwick University in Finance and M&A, and a PhD from Edinburgh University in epigenetics.

Dr Adrian Dawkes - Vice President, PharmaVentures Since joining PharmaVentures in 2007, Adrian has led a number of consultancy and licensing mandates and is increasingly involved in M&A. Among his successful projects at PharmaVentures is the recent acquisition of NanoSight Ltd. by the UK plc Spectris.

Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. He has held senior positions in diagnostics and therapeutics with Johnson & Johnson, Acumen Bioscience and the Healthcare Consultancy Execute Technologies. Adrian has over 28 years in the pharmaceutical, biotechnology and in vitro diagnostics sectors. An Oxford Brookes alumnus, Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Hakan Goker, Investment Director, MS Ventures Hakan Goker (Ph.D.) is a director at MS Ventures, the corporate venture capital fund of Merck Serono. Previously, Hakan was a partner at Aescap Venture which he joined in 2010 investing in European private biotechnology and medical technology companies. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation, financing, business and R&D strategy of various companies including Orphazyme (DK), F Star (NL), Actogenix (BE), Bicycle Therapeutics (UK), Nimbus Discovery (US), Lumavita (CH), Nitec now Horizon Pharma (CH/US), Protaffin (AU/UK), and Egalet (DK). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Forendo Pharma and Synaffix BV and is acting CBO of Asceneuron SA. Tony Jones , Director of Business Development, One Nucleus After completing a PhD in Biochemistry (1992) from the University of Southampton UK, Tony undertook several years of post-doctoral research in the oncology field, primarily with the Imperial Cancer Research Fund (now CRUK). In 1997, he moved into Technology Transfer with the Medical Research Council and later (1998) University College London, at the Wolfson Institute for Biomedical Research. In November 2003, Tony took up the post of Director of Biotechnology & Healthcare at London First, managing the London Biotechnology Network and promotion of London’s excellence in healthcare research and delivery. In May 2010 he took London Biotechnology Network into the merger with ERBI, seeing this as the best manner in which to continue assisting member companies develop their businesses.

As Director of Business Development his role at One Nucleus encompasses the development of the membership offer to reflect the current external environment and changing needs placed upon members’ businesses. He leads on delivery of the BioWednesdays, the Life Science Leadership Series and the annual Genesis Conference.

Dr Rajendra Kumari, Chief Scientific Officer, Crown Bioscience UK Rajendra received her Ph.D. in Molecular Pharmacology from the University of Leicester and after postdoctoral fellowships in the Division of Pre-clinical Oncology, University of Nottingham (UoN), became a Lecturer within the School of Clinical Sciences building expertise in cancer cell biology, preclinical modelling (patient-derived xenografts, cell line models and imaging) and the tumour microenvironment. Rajendra is a co-founder of the spinout company Preclinical Oncology Services Ltd (PRECOS) which was a business Unit within the UoN where Rajendra managed a portfolio of preclinical projects, products, team and clients. Rajendra was pivotal in the growth of the business unit, marketing and commercialisation of research becoming Chief Operations Officer in 2010 at spinout until merger with Crown Bioscience in July 2013 and now acts as Chief Scientific Officer leading scientific strategy, R&D and scientific operations for Crown Bioscience UK in Loughborough.

Florence L’Hospice, Innate Pharma Florence L’Hospice, pharm D joined Innate Pharma in 2002. She completed pharmacy study at University of Joseph Fourier (France) and University of Montreal. She started working on small molecule targeting T lymphocyte in the CMC field. In 2008 she moved into monoclonal antibody development. She became responsible for the CMC development (Quality and viral safety part) of an IgG4 targeting KIR2DL3 antigen. The antibody has been out-licensed to Bristol Myers Squibb in 2011 (in phase I), Florence was responsible for the data and known-how transfer to BMS team.

Since 2012, merging small molecule and monoclonal antibody universe, Florence have been leading the ADC program focusing on new site specific conjugation technology.

Stephen Megit, Director of Business Development, Immunocore Having gained his Ph.D. in molecular biology Steve has spent over 15 years in biotech business development on both small molecules and biologics. Within Immunocore Steve has been instrumental in shaping the company’s international IP strategy to protect its revolutionary ImmTAC platform technology and delivering partnerships with Genentech, GSK, MedImmune, and most recently Eli Lilly.

Neill Moray Mackenzie, Ph.D., Chief Business Officer, Biotecnol Limited Neill is an internationally networked pharmaceutical executive and a serial entrepreneur with extensive operational, commercial, licensing and R&D background in academia, pharma and biotech companies. After completing his PhD in immunology and Postdoctoral work at the National Institute for Medical Research with the MRC, he became the Wellcome Trust lecturer in immunology in the University of London. He joined Wellcome plc as Head of the Immunology and Anti-infectives Department continuing with Mallinckrodt Inc. after it acquired the Division. Over the last nineteen years, he has served on the Boards biotech companies in the immunology and immune-oncology space. Serving in Trimunocor Ltd as founder and CEO (current), Biotecnol Ltd as CBO (current), Cellular therapeutics Ltd as a non-exec director (current), CMP Therapeutics Ltd as CEO, Roji Ltd as founder and CEO, Medigene AG (listed on the German Börse) as SVP Business Development and Commercial Strategy, Avidex Ltd, as CBO, Oxford BioMedica plc (listed on the LSE), and BioMedica Inc as co-founder and EVP of Business development and Corporate Strategy and with Cambridge Genetics Ltd., he was the co-founder and CEO. In these companies he took primary responsibility all elements of corporate business development, including M&A, partnering, licensing, PR and IR. As an Executive Director with P&L responsibilities, in listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market) and private companies he has raised over $150 million equity capital from private and public funds and completed numerous deals with pharmaceutical companies globally.

Ian Miscampbell, Managing Partner, Sixth Element Capital LLP After qualifying with KPMG as a Chartered Accountant in 1987, Ian moved into the life sciences arena in the late 1990s. Since then he has served as CFO / Finance Director and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. Having spent a short period working as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital. In March 2012 he was instrumental in raising Sixth Element’s first fund, the CRT Pioneer Fund, a £70m project finance based fund focused exclusively on the European oncology sector. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.

Alain Rachon, Business Developer Biotech Start-up, Merck Millipore Alain Rachon is Business Developer on the Biotechnology start-up market at Merck Millipore, the Life Science Division of Merck KGa. In his role, he is accountable of creating a business strategy to identify innovative start-up companies working on biological molecules pipeline, understand their development strategies and propose a global offer to speed them up to clinic. Alain cumulates 25 years of experience within the Biopharmaceutical industry. Previously, he took several sales and marketing roles with management responsibilities at Millipore with a strong focus on single use technologies integration all along the biodevelopment & bioproduction phases. Alain received a Master Degree in Biochemistry and Enzymology from the University of Nancy I. He is currently board member of A3P, a European Biopharm Association having the objective to create a professional network between Pharma users & Suppliers around the industry and regulatory trends & innovations.

Dr Richard Turner, Principal Consultant, Clinical Network Services (UK) Dr Richard Turner, BioDesk’s Principal Consultant in the UK office, is a former pharmaceutical and scientific assessor at the Medicines Control Agency (now known as the UK MHRA). Dr Turner joined CNS from Daiichi Sankyo where he was Director of Regulatory Affairs and has also worked in senior regulatory roles including Head of International Regulatory Affairs at Lonza Biologics, Director of Regulatory Affairs at ERA Consulting, Associate Director at Elan and Antisoma. Dr Turner has a PhD in Microbial Biochemistry and started his career as a research scientist working on development of recombinant protein therapeutics at Delta Biotechnology in Nottingham UK. Viia Valge-Archer, Principal Scientist, Oncology, MedImmune Viia Valge-Archer (Ph.D.) is Principal Scientist in Oncology in MedImmune with 15 years’ experience in biologics drug discovery and leadership in new target identification and validation.

Tamara Wells, Director, Global Business Development Oncology, Merck Serono Tamara is a Director in the Global Business Development Oncology team; she joined Merck KGaA in Germany in 2013 and has already secured key deals for Merck. Tamara brings with her a wealth of business experience having worked in several biotech companies. Prior to joining Merck, Tamara was VP Business Development at Dutch biotech Lanthio Pharma, where she played a key role in securing funding and collaboration deal with MorphoSys. Prior to Lanthio Pharma, Tamara worked as Business Development Director at Amsterdam Molecular Therapeutics (now uniQure), a stock market quoted company where she was a member of the Management team, and secured several product development collaborations. Tamara worked in a range of leadership roles in UK companies Eden Biodesign (now Actavis) in Liverpool and Lorantis (now Celldex Therapeutics) in Cambridge.

Tamara holds a PhD in biochemistry from University College London where she studied under the leadership of Sir Tim Hunt, a Nobel Prize winner. Tamara also holds a MBA from London Business School.

WIFI details SSID: OneNucleus Username: OneNucleus_1 Password: GreenDr&gon